BRAND NAMES
 MECHANISM OF ACTION
Nabumetone is a nonselective non-steroidal anti-inflammatory drug (NSAID). After absorption, nabumetone undergoes rapid biotransformation to the principal active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA).
6MNA inhibits the cyclooxygenase enzyme and preferentially blocks COX-2 activity (which is indirectly responsible for the production of inflammation and pain during arthritis).
Nabumetone is used to treat arthritic symptoms such as swelling, stiffness and joint pain. NSAIDs do not cure arthritis, but they promote suppression of the inflammation and the tissue damaging effects resulting from this inflammation.
Generally, patients are instructed to take 1000 mg once a day at bedtime.. During treatment, the doctor may decide to increase the dosage up to 2000 mg each day, according to the response to the medication. In that case it may be divided in two doses per day.
- Hypersensitivity to Namubetone
- Namubetone is also contraindicated in patients in whom aspirin, or other NSAIDs induce asthma, urticaria, or other allergic-type reactions. Fatal asthmatic reactions have been reported in such patients receiving NSAIDs.
- Last three months of pregnancy or breastfeeding
- Have or have had a peptic ulcer
- Have severely impaired liver or kidney function
- Have severe heart failure or severely impaired heart function
- Have an uncorrected blood clotting disorder
- Serious gastrointestinal toxicity such as bleeding, ulceration, and perforation can occur at any time in patients treated chronically with NSAID therapy. Large-scale database studies indicate that risk of serious GI complications is lower with nabumetone than comparator NSAIDs.
- Caution should be exercised when administering Nabumetone with warfarin since interactions have been seen with other NSAIDs.
 PREGNANCY AND LACTATION
- Pregnancy Category C (US). There are no adequate, well-controlled studies in pregnant women. Nabumetone should be used during pregnancy only if clearly needed. Because of the known effect of prostaglandin-synthesis-inhibiting drugs on the human fetal cardiovascular system (closure of ductus arteriosus), use of Nabumetone during the third trimester of pregnancy is not recommended.
- Nursing Mothers: is not recommended for use in nursing mothers
 SIDE EFFECTS
The most frequently reported adverse reactions were related to the gastrointestinal tract and included diarrhea, dyspepsia, and abdominal pain.
 RELATED LINKS
|Non-steroidal anti-inflammatory drugs (NSAIDs)|
|Non-selective (COX-1 and COX-2 inhibitors)||Aceclofenac • Acetylsalicylic acid • Benzydamine • Diclofenac • Flurbiprofen • Ibuprofen • Indometacin • Ketoprofen • Ketorolac • Ketorolac • Lornoxicam • Mefenamic acid • Morniflumate • Nabumetone • Naproxen • Niflumic acid • Piroxicam • Tenoxicam|
|Relatively COX-2 selective||Meloxicam • Nimesulide|
|COX-2 selective inhibitors (Coxibs)||Celecoxib • Etoricoxib • Parecoxib|
|Ophthalmic NSAIDs||Bromfenac (ophthalmic) • Diclofenac (ophthalmic) • Flurbiprofen (ophthalmic) • Ketorolac (ophthalmic) • Nepafenac (ophthalmic)|
|Veterinary use||Carprofen • Deracoxib • Firocoxib • Mavacoxib • Robenacoxib|